SEDECAL SA recalled 1,198 units of its MobileDiagnost wDR 2.2 X-ray system on June 10, 2025. The equipment is not water-resistant and may pose hazards if not cleaned according to the manual. Users must stop using the device immediately and contact the manufacturer for further instructions.
Sedecal sent an email to its consignees to remind the users that the equipment is not water-resistant and must be cleaned strictly according to the instructions in the manual, clearly outlining the possible consequences of improper cleaning.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact SEDECAL SA or your healthcare provider for instructions. Notification method: E-Mail
The MobileDiagnost wDR 2.2, Model Number REF 9890-010-89522, was distributed in California, Illinois, and New Jersey. The recall affects a total of 1,198 units.
The MobileDiagnost wDR 2.2 is not water-resistant. Improper cleaning can lead to serious equipment malfunction and possible injury.
No specific incidents have been reported. However, the potential for equipment failure due to improper cleaning poses a significant risk.
Stop using the device immediately. Follow the manufacturer's recall instructions and contact SEDECAL SA or your healthcare provider for guidance.
For further details, visit the FDA recall page at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=Z-0243-2026 or contact SEDECAL SA.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.